Develops pharmaceutical products targeting anti-viral treatments. Manufactures drugs for endocrine and metabolic diseases. Now — the numbers.
This is an established company with proven profits.
Average growth of 12% a year over the last 4 years. Red columns mark years that ended in a loss.
The gap is $123.5M. In times of high interest rates, a gap like that can squeeze a company.
The market pays 8.9× for every dollar of annual profit — cheap, which is either an opportunity or a warning.
No analyst target is on record for this company.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Over the last 4 years, sales grew about 12% a year on average.
It pays out $0.19 per share each year — regular cash for whoever holds the stock.
The stock sits at $0.55. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
The price action doesn’t yet back an upward turn. Council score: 0/10.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: earnings execution, the revenue breakdown.